Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors

Bonetti, Andrea; Franceschi, T.; Apostoli, P; Messori, Andrea; Sperotto, L.; Cetto, Gian Luigi; Molino, Annamaria; Leone, Roberto

doi:10.1097/00007691-199502000-00005

Cited by 22 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 shows the results of the chemosensitivity assays for 14 drugs tested against the three carcinoid cell lines. The IC 50 values were compared to the following individual achievable peak plasma concentrations (PPC): vinblastine 8.5 ng/ml [22], taxol 3.5±1.4 µM [23], camptothecin derivative topotecan (TPT) 65±20 nM [24], 5-FU 0.6 µM/l [25], doxorubicin 73.5±26.4 ng/ml [26], gemcitabine 50 µM [27], tamoxifen 0.4 µM [28], cisplatin 6.3 µM [29], oxaliplatin 9.1±1.25 µM [30], carboplatin 105 µM [31], mitomycin C 345±151 ng/ml [32], streptozotocin 100±10 µg/ml [33], etoposide 5.6±2.5 µg/ml [34] and dacarbazine 8.6±0.6 µg/ml [35]. UMC-11 cells exhibited marked chemoresistance against most drugs, with the exception of vinblastine, camptothecin, oxaliplatin, carboplatin, mitomycin C and dacarbazine, where IC 50 values were below PPC for the respective drugs.…”

Section: Resultsmentioning

confidence: 99%

In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines

et al. 2011

View full text Add to dashboard Cite

The highly resistant UMC-11 lung carcinoid cells are sensitive to carboplatin, oxaliplatin and the satraplatin metabolite JM118, but multicellular spheroidal growth, as observed in the H835 cell line and pulmonary tumourlets, seems to increase chemoresistance markedly. The activity of carboplatin and JM118 is significantly and specifically increased in combination with the apoptosis sensitiser DCA that promotes mitochondrial respiration over aerobic glycolysis. In summary, among the novel platinum drugs satraplatin has the potential for treatment of lung carcinoids and DCA potentiates the cytotoxicity of selected platinum drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Excretion of cisplatin is mainly renal. Residual levels of ultrafiltrable and total platinum steadily increase from course to course (Bonetti et al 1995;Gamelin et al 1995).…”

Section: The First Generation -Cisplatinmentioning

confidence: 97%

Tumour-inhibiting platinum complexes—state of the art and future perspectives

Jakupec

Galanski

Keppler

2003

Reviews of Physiology, Biochemistry and Pharmacology

383

349

View full text Add to dashboard Cite

Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field of research. This article reviews the current preclinical and clinical status, including a discussion of the molecular basis for the activity of the parent drug cisplatin and platinum drugs of the second and third generation, in particular their interaction with DNA. Further emphasis is laid on the development of third generation platinum drugs with activity in cisplatin-resistant tumours, particularly on chelates containing 1,2-diaminocyclohexane (DACH) and on the promising and more recently evolving field of non-classic ( trans- and multinuclear) platinum complexes. The development of oral platinum drugs and drug targeting strategies using liposomes, polymers or low-molecular-weight carriers in order to improve the therapeutic index of platinum chemotherapy are also covered.

show abstract

“…Many studies have shown that borneol can loosen the BBB and can thus effectively improve the permeability of drugs through the BBB and increase drug concentrations in the brain (Chen & Wang 2004;Li et al 2004;Jia et al 2010). cisDiaminedichloroplatinum(II) (cisplatin), an antitumour agent, is widely used in the treatment of several malignancies because of its potent cytotoxic effects on a variety of tumour types, including testicular, ovarian and cervical carcinoma (Bonetti et al 1995;Lehman & Thomas 2001;Dasari & Bernard Tchounwou 2014). However, because of the poor permeability of the BTB, cisplatin does not always have a satisfactory curative effect when used for the treatment of brain tumours (Groothuis 2000;Ebrahimi Shahmabadi et al 2014).…”

Section: Introductionmentioning

confidence: 99%

Borneol increases blood–tumour barrier permeability by regulating the expression levels of tight junction-associated proteins

Duan

Xing

Guo

et al. 2016

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Selectively opening the blood-tumour barrier (BTB) is critical to deliver antitumour drugs from blood to tumour tissues. The BTB problem is attributed to the tight junctions (TJs), which consist of several transmembrane proteins. Objective: To investigate whether borneol could open the BTB by affecting TJ-associated proteins ZO-1, occludin, claudin-5 and F-actin in the rat model of C6 glioma. Materials and methods: The plasma and brain tissue of C6 glioma rats were collected at different points after rats were administered with 35 or 140 mg/kg borneol and 0.5% CMC-Na, respectively. The permeability of BTB was assessed by cisplatin extravasation. The mRNA and protein expression levels of TJ-associated proteins were determined by QPCR, ELISA and immunohistochemistry. Results: The cisplatin bioavailability in the brain tissue of C6 glioma rats administered either 35 or 140 mg/kg borneol and 0.5% CMC-Na were 415.07, 227.04 and 192.07 (mg/mL/h), respectively. The mRNA and protein expression levels of ZO-1 and F-actin began to decrease from the time point of 2 min; the lowest levels in the borneol high-dose (46.7% decrease for ZO-1 and 63.3% for F-actin compared with control) and low-dose groups (54.3% for ZO-1; 77.9% for F-actin) appeared at the time points of 30 and 45 min, respectively. Thereafter, the levels were gradually restored to the level of borneol at 0 h. Occludin and claudin-5 expression levels were not significantly modified. Conclusion:Borneol could selectively open the BTB and consequently increase BTB permeability, and this mechanism is associated with the down-regulation of ZO-1 and F-actin. ARTICLE HISTORY

show abstract

Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors

Cited by 22 publications

References 0 publications

In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines

In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines

Tumour-inhibiting platinum complexes—state of the art and future perspectives

Borneol increases blood–tumour barrier permeability by regulating the expression levels of tight junction-associated proteins

Contact Info

Product

Resources

About